Tumour Cell Products and Interleukin 2 Production
Author Information
Author(s): M. Nelson, J.A.G. Bremner, D.S. Nelson
Primary Institution: Kolling Institute of Medical Research, Royal North Shore Hospital
Hypothesis
Can tumour cell products inhibit interleukin 2 production by human blood lymphocytes?
Conclusion
Tumour cell products significantly inhibit the production of interleukin 2 by human lymphocytes.
Supporting Evidence
- Tumour supernatants inhibited IL2 production by 24-87%.
- Inhibition was dose dependent.
- Fibroblasts had no significant effect on IL2 production.
- IL2 production was measured using both bioassay and immunoassay methods.
- High correlation (r=0.90) was found between the two assays.
Takeaway
Tumours can make substances that stop our body's immune cells from making a helper protein called interleukin 2, which is important for fighting off diseases.
Methodology
Human blood lymphocytes were cultured with tumour supernatants and stimulated to measure interleukin 2 production.
Potential Biases
Potential bias in selecting tumour types and donor variability.
Limitations
The study primarily focused on specific tumour types and may not represent all cancers.
Participant Demographics
Lymphocytes from eight different normal human donors were used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website